Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Basilea Pharmaceutica AG (BSLN.SW)
Allschwil, CH
Basilea Pharmaceutica AG operates as a commercial-stage biopharmaceutical enterprise, concentrating its efforts on inventing and advancing treatments to address critical unmet medical needs within the therapeutic fields of oncology and anti-infectives. Its commercialized offerings include Cresemba, an azole antifungal drug available in both intravenous and oral formulations, utilized for managing invasive aspergillosis and mucormycosis in the United States and the European Union; this drug is also advancing through Phase III clinical trials in Japan for various invasive fungal infections. The company additionally provides Zevtera, an antibiotic targeting community and hospital-acquired pneumonia, which is also undergoing Phase III clinical development for acute bacterial skin and skin structure infections, along with Staphylococcus aureus bacteremia. Beyond its current portfolio, Basilea's pipeline features Derazantinib, a small molecule inhibitor in Phase 2 clinical trials for bile duct cancer, and in Phase 1/2 trials for both bladder and stomach cancers, as well as Lisavanbulin, a novel tumor checkpoint controller drug. Established in 2000, Basilea Pharmaceutica AG maintains its corporate headquarters in Basel, Switzerland.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.76% | -2.43% | -4.23% | -5.62% | +6.22% | -4.40% | +15.39% | +11.68% | +19.00% | -33.38% | -48.06% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 2 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+11.4% ★ Q4'25: +76.6% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%-46.1% Q4'25: +212.4% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%+23.6% Q4'25: +28.6% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%+22.2% ★ Q4'25: +21.5% (vs Q4'23)
-
ROIC Biotechnology: -16.1%+68.1% ★ Q4'25: +152.9% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%-7.6% ★ Q4'25: +1.7% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×1.96× ★ Q4'25: 0.92× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 4 EPS Ana. |
Dec 2027 3 Rev. Ana. 3 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
52.83M
est: 56.10M (-5.8%)
|
65.98M
est: 64.60M (+2.1%)
|
101.52M
est: 93.46M (+8.6%)
|
132.56M
est: 125.28M (+5.8%)
|
134.38M
est: 134.76M (-0.3%)
|
127.63M
est: 130.35M (-2.1%)
|
148.12M
est: 142.50M (+3.9%)
|
147.77M
est: 124.24M (+18.9%)
|
157.63M
est: 149.02M (+5.8%)
|
208.54M
est: 198.34M (+5.1%)
|
232.40M
est: 222.21M (+4.6%)
|
257.36M
257.31M – 257.42M
+15.8% YoY
|
263.19M
239.48M – 290.42M
+2.3% YoY
|
221.76M
211.87M – 231.65M
-15.7% YoY
|
201.82M
192.52M – 212.50M
-9.0% YoY
|
243.72M
232.49M – 256.62M
+20.8% YoY
|
| EBITDA |
-58.84M
est: 7.35M (-900.6%)
|
-41.67M
est: 8.46M (-592.4%)
|
-7.30M
est: 12.24M (-159.7%)
|
-22.76M
est: 16.41M (-238.6%)
|
-14.32M
est: 17.65M (-181.1%)
|
-2.24M
est: 17.08M (-113.1%)
|
6.72M
est: 18.67M (-64.0%)
|
26.21M
est: 16.28M (+61.0%)
|
23.19M
est: 26.66M (-13.0%)
|
63.13M
est: 35.49M (+77.9%)
|
51.60M
est: 39.76M (+29.8%)
|
46.05M
46.04M – 46.06M
+15.8% YoY
|
47.09M
42.85M – 51.96M
+2.3% YoY
|
39.68M
37.91M – 41.45M
-15.7% YoY
|
36.11M
34.45M – 38.02M
-9.0% YoY
|
43.61M
41.60M – 45.91M
+20.8% YoY
|
| EBIT |
-61.37M
est: 6.54M (-1,038.6%)
|
-44.54M
est: 7.53M (-691.7%)
|
-12.35M
est: 10.89M (-213.4%)
|
-24.61M
est: 14.60M (-268.5%)
|
-15.96M
est: 15.70M (-201.6%)
|
-21.41M
est: 15.19M (-241.0%)
|
4.27M
est: 16.61M (-74.3%)
|
23.11M
est: 14.48M (+59.6%)
|
21.66M
est: 25.04M (-13.5%)
|
61.70M
est: 33.33M (+85.1%)
|
51.60M
est: 37.34M (+38.2%)
|
43.25M
43.24M – 43.26M
+15.8% YoY
|
44.23M
40.24M – 48.80M
+2.3% YoY
|
37.26M
35.60M – 38.93M
-15.7% YoY
|
33.91M
32.35M – 35.71M
-9.0% YoY
|
40.96M
39.07M – 43.12M
+20.8% YoY
|
| Net Income |
-61.60M
est: -72.74M (+15.3%)
|
-51.29M
est: -68.17M (+24.8%)
|
-19.36M
est: -31.67M (+38.9%)
|
-31.35M
est: -39.98M (+21.6%)
|
-22.42M
est: -33.03M (+32.1%)
|
-14.72M
est: -26.52M (+44.5%)
|
-6.83M
est: -24.11M (+71.7%)
|
12.15M
est: -15.96M (+176.1%)
|
10.45M
est: -652.0K (+1,702.9%)
|
77.59M
est: 56.05M (+38.4%)
|
40.20M
est: 40.24M (-0.1%)
|
52.62M
47.32M – 62.46M
+30.8% YoY
|
63.82M
22.33M – 76.97M
+21.3% YoY
|
10.02M
9.38M – 10.67M
-84.3% YoY
|
43.79M
41.16M – 46.80M
+336.9% YoY
|
78.35M
73.66M – 83.74M
+78.9% YoY
|
| SGA |
54.24M
est: 11.28M (+380.8%)
|
56.08M
est: 12.99M (+331.8%)
|
51.58M
est: 18.79M (+174.5%)
|
30.47M
est: 25.19M (+21.0%)
|
30.05M
est: 27.09M (+10.9%)
|
29.42M
est: 26.21M (+12.3%)
|
29.72M
est: 28.65M (+3.7%)
|
30.82M
est: 24.98M (+23.4%)
|
33.78M
est: 27.66M (+22.2%)
|
31.54M
est: 36.81M (-14.3%)
|
35.60M
est: 41.24M (-13.7%)
|
47.76M
47.75M – 47.77M
+15.8% YoY
|
48.84M
44.44M – 53.90M
+2.3% YoY
|
41.16M
39.32M – 42.99M
-15.7% YoY
|
37.46M
35.73M – 39.44M
-9.0% YoY
|
45.23M
43.15M – 47.63M
+20.8% YoY
|
| EPS |
-6.09
est: -5.25 (-16.0%)
|
-5.07
est: -4.92 (-3.0%)
|
-1.79
est: -2.29 (+21.7%)
|
-2.89
est: -2.89 (-0.1%)
|
-2.08
est: -2.38 (+12.7%)
|
-1.43
est: -1.91 (+25.3%)
|
-0.58
est: -1.74 (+66.7%)
|
1.02
est: -1.18 (+186.8%)
|
0.87
est: -0.05 (+1,707.2%)
|
6.42
est: 4.36 (+47.3%)
|
3.29
est: 3.05 (+7.9%)
|
4.18
3.70 – 4.88
+37.0% YoY
|
3.06
1.74 – 6.01
-26.6% YoY
|
0.78
0.73 – 0.83
-74.6% YoY
|
3.42
3.22 – 3.66
+338.8% YoY
|
6.12
5.75 – 6.54
+78.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-28 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-27 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-26 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-22 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-21 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-20 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-19 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-18 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-15 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-13 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-12 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-11 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-06 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-05 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-04 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-29 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares International Developed Small Cap Value Factor ETF ISVL | 0.12% | 378.4K | 0.31% |
| 2 | Avantis International Small Cap Value ETF AVDV | 0.10% | 18.57M | 0.36% |
| 3 | iShares MSCI Europe Small-Cap ETF IEUS | 0.05% | 95.7K | 0.41% |
| 4 | Xtrackers MSCI Europe Small Cap UCITS ETF 1C XXSC.L | 0.05% | 1.83M | 0.30% |
| 5 | Xtrackers MSCI World Swap UCITS ETF 1C XMWD.L | 0.05% | 6.78M | 0.45% |
| 6 | Xtrackers - Xtrackers MSCI World Swap UCITS ETF 4C - EUR Hedged XWEH.DE | 0.05% | 6.77M | 0.39% |
| 7 | iShares Core SPI(R) ETF (CH) CHSPI.SW | 0.03% | 2.45M | 0.10% |
| 8 | State Street SPDR S&P International Small Cap ETF GWX | 0.03% | 287.2K | 0.40% |
| 9 | Schwab International Small-Cap Equity ETF SCHC | 0.03% | 1.75M | 0.06% |
| 10 | Avantis Global Small Cap Value UCITS ETF AVGS.L | 0.03% | 322.2K | 0.39% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| David Veitch | Chief Executive Officer | 1M | male |
| Andreas Kumin | Head of Corporate Development | — | male |
| Damian Heller | General Counsel & Corporate Secretary | — | male |
| Gerrit Hauck | Chief Technology Officer | — | — |
| Laurenz Kellenberger | Chief Scientific Officer | — | — |
| Marc Engelhardt | Chief Medical Officer | — | — |
| Mark Jones | Head of Global Affairs | — | male |
| Peer Nils Schroder | Head of Corporate Communications & Investor Relations | — | — |
| Adesh Kaul | Chief Financial Officer | — | male |
| Ursula Eberhardt | Head of Global Human Resources | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BSLN.SW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
